- Home
- ACT vs PRCT Comparison
ACT vs PRCT Comparison
Compare ACT & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACT
- PRCT
- Stock Information
- Founded
- ACT 1981
- PRCT 2009
- Country
- ACT United States
- PRCT United States
- Employees
- ACT N/A
- PRCT N/A
- Industry
- ACT Specialty Insurers
- PRCT Medical Specialities
- Sector
- ACT Finance
- PRCT Health Care
- Exchange
- ACT Nasdaq
- PRCT Nasdaq
- Market Cap
- ACT 5.2B
- PRCT 5.3B
- IPO Year
- ACT 2021
- PRCT 2021
- Fundamental
- Price
- ACT $34.76
- PRCT $93.60
- Analyst Decision
- ACT Buy
- PRCT Strong Buy
- Analyst Count
- ACT 4
- PRCT 6
- Target Price
- ACT $36.25
- PRCT $89.50
- AVG Volume (30 Days)
- ACT 604.9K
- PRCT 1.2M
- Earning Date
- ACT 11-06-2024
- PRCT 10-28-2024
- Dividend Yield
- ACT 2.06%
- PRCT N/A
- EPS Growth
- ACT 6.96
- PRCT N/A
- EPS
- ACT 4.29
- PRCT N/A
- Revenue
- ACT $1,196,188,000.00
- PRCT $199,843,000.00
- Revenue This Year
- ACT N/A
- PRCT $67.06
- Revenue Next Year
- ACT $4.91
- PRCT $40.59
- P/E Ratio
- ACT $8.11
- PRCT N/A
- Revenue Growth
- ACT 5.45
- PRCT 71.71
- 52 Week Low
- ACT $26.13
- PRCT $33.45
- 52 Week High
- ACT $37.42
- PRCT $103.81
- Technical
- Relative Strength Index (RSI)
- ACT 53.41
- PRCT 57.39
- Support Level
- ACT $33.54
- PRCT $85.75
- Resistance Level
- ACT $35.09
- PRCT $95.36
- Average True Range (ATR)
- ACT 0.65
- PRCT 4.38
- MACD
- ACT 0.14
- PRCT -0.61
- Stochastic Oscillator
- ACT 87.64
- PRCT 43.47
About ACT Enact Holdings Inc.
Enact Holdings Inc is a private mortgage insurance company serving the United States housing finance market. The principal mortgage insurance customers are originators of residential mortgage loans who determine which mortgage insurer or insurers they will use for the placement of mortgage insurance written on loans they originate. The company is engaged in the business of writing and assuming residential mortgage guaranty insurance.
About PRCT PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System,, image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. The company's assets are based in the United States. Its revenue is generated from sales of the AquaBeam Robotic System and the accompanying single-use disposable handpieces.